Henlius

#HenliusMedicalHub We're thrilled to share that several clinical studies on serplulimab — the first anti-PD-1 mAb approved for 1L small cell lung cancer — demonstrated breakthrough results in lung & GI cancers at #ASCO 2025. Key highlights: ✅ Significant 4-year OS rate (21.9%) in patients with extensive-stage small cell lung cancer (ASTRUM-005) ✅ Robust efficacy in 10+ gastrointestinal cancers studies 🌍Science without borders — Henlius is committed to transforming outcomes for cancer patients worldwide. #CancerResearch Learn More：https://lnkd.in/dDJH4Cas

#HenliusinFocus 🔔 Henlius will participate in the Jefferies Global Healthcare Conference, June 3-5 in New York. Our CEO, Jason Zhu MD MBA, will engage with over 3,000 industry leaders and investors to discuss the latest trends and opportunities in biopharma. 📅 Mark your calendar to connect with us and discuss potential collaborations! #JefferiesHealthcare

#HenliusinFocus What defines a Next-Generation Biotech Partner? At Henlius, we embody this through: 🔬 The Innovator - Pioneering novel therapies 🌍 The Globalizer - Delivering worldwide access 🤝 The Collaborator - Building strategic alliances   Join us at BIO 2025 Booth#1885 to see how our: ✅ 6 commercialized products ✅ 20+ innovative mAbs ✅ 800,000+ patients served ...are shaping the future of biotech partnerships. Let's redefine healthcare together.

#HenliusMedicalHub Milestone Achieved:  HLX22, our innovative anti-HER2 mAb, has been granted #OrphanDrug Designation (ODD) by the European Commission for #GastricCancer. To date, it is the world's first anti-HER2 therapy for gastric cancer with dual ODD approvals from both the FDA and EC! 🎉   The ODD unlocks key EU incentives, including: 🔹 10 years of market exclusivity post-approval 🔹 Protocol assistance for clinical development 🔹 Fee reductions and regulatory support 🔹 Access to the centralized authorization procedure   HLX22's ODD brings us closer to transforming outcomes for rare disease communities. 💡#RareDisease   Learn More: https://lnkd.in/dBhWRrsS

🔬#HenliusMedicalHub Hot off Henlius' Post-ASCO 2025 Business Update: 📅 June 2, 2025 (Chicago) 💡 Explore our latest oncology data and global development strategies with industry leaders. 📍 Chicago (in-person) or virtual 🔗 Register now! #ASCO2025 #Innovation

#HenliusinFocus We're proud to announce that Henlius has successfully upgraded to the ISO/IEC 27001:2022 standard for our Information Security Management System (ISMS), endorsed by CNAS, ANAB & UKAS—the highest global benchmark for data security.. This milestone reflects our focus on cybersecurity, cloud safety, and privacy protection, ensuring trust for patients and partners worldwide. 🌍 Together, strengthening our global digital resilience. #CyberSecurity #Biopharma Learn More：https://lnkd.in/d5g4B8WC

🔬#HenliusMedicalHub At Henlius, we're proud to advance our mission of high-quality, affordable biologics worldwide. With 70+ clinical trial approvals and 8,700+ patients enrolled across global studies, we're accelerating breakthroughs to transform lives.🌍 Grateful to our teams and partners pushing boundaries together! 👏 #InternationalClinicalTrialsDay

#HenliusInFocus Milestone Achieved: Henlius has dosed the first patient in the Phase 1/3 clinical study of HLX13, our ipilimumab #biosimilar candidate.   Together with our partners including Sandoz, we're one step closer to bring high-quality, affordable treatment to patients worldwide.   Read the #news: https://lnkd.in/dew8Y6U7

#HenliusinFocus We're proud to announce our inclusion in the #MSCl Global Small Cap Indexes - a testament to our overall strength and global growth potential recognized by institutional investors worldwide. As a profitably listed biopharma (HKEX: 2696), this marks a leap in our internationalvisibility and opens doors to broader capital markets. Stay tuned as we accelerate global access to innovative biologics! #Biopharma#Innovation #Investment Learn More: https://lnkd.in/dtVGJZ5n

#HenliusinFocus Mark your calendars for June 16-19 in Boston! We're excited to showcase our extensive product portfolio during #BIO2025. Be sure to stop by Booth#1885 to connect with the Henlius team and our SVP & Chief Business Officer, Ping Cao —we're ready to explore new global ties and partnerships! 💡 Perfect opportunity to discover our game-changers: serplulimab (1st anti-PD-1 in 1L SCLC) HLX22 (FDA ODD-designated anti-HER2 mAb) HLX43 (PD-L1 ADC - 2nd in clinical stage globally) Save the date & let's advance oncology innovation together. #Innovation #CancerResearch